Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.

View through CrossRef
Abstract Numerous drugs are known to cause immune thrombocytopenia (TP) mediated by antibodies (abs) that bind to platelets only when the sensitizing drug is present in soluble form. The widely used antibiotic, vancomycin, has been implicated as a cause of TP only in 8 case reports and little is known about antibodies possibly responsible for this complication. We characterized clinical and serologic aspects of TP occurring in 39 patients during treatment with vancomycin. In this group, TP developed after 1–27 days of treatment (median 6 days) and plt nadirs ranged from 1,000 to 60,000 plts/uL (median 14,000 plts/uL). Bleeding occurred in 14 patients and contributed to a fatal outcome in 3. TP persisted for 1–17 days after discontinuing vancomycin (median 7 days). Platelets eventually returned to baseline in all surviving patients. Serum obtained after the onset of TP was studied for vancomycin-dependent, platelet-reactive abs by flow cytometry and by solid phase ELISA using immobilized plt glycoproteins (GP) as targets. Vancomycin-dependent antibodies detected in patients and normal subjects IgG only IgM only IgG + IgM No antibody Total Patients with TP 21 (54%) 5 (13%) 13 (33%) (0)%) 39 Normal individuals 58 (21%) 4 (1%) 1 (0%) 210 (77%) 273 Results of flow cytometric studies are summarized above. All patients had IgG and/or IgM abs that reacted with normal plts in the presence, but not in the absence of vancomycin. The IgG mean fluorescence intensity (MFI) signal in the presence of drug was 1.6 to 32.0 times stronger (mean ratio 5.7) than that obtained in the absence of drug. Vancomycin-dependent IgG abs were also identified in 59 of 273 normal individuals but were much weaker than abs detected in patients (p = 0.004). IgM abs (mean ratio 5.7, range 1.6 – 34) were found in 18 of 39 patients (46%). Weaker IgM abs were found in only 5 of 273 normal subjects (1.8%) (p = 0.001). Two patient abs studied in ELISA reacted preferentially with GPIIb/IIIa. Studies to determine the frequency of abs in patients given vancomycin who do not develop TP are in progress. These findings provide evidence that TP in patients given vancomycin can be caused by drug-dependent abs specific for GPIIb/IIIa that are stimulated by vancomycin exposure. IgG and IgM abs in patients with TP are generally much stronger than drug-dependent, platelet-reactive immunoglobulins found in some normal subjects. The significance of the latter abs is presently unknown. Drug-dependent IgM abs are found almost exclusively in patients with vancomycin-associated TP and may be diagnostic. Patients treated with vancomycin often have life-threatening bacterial sepsis and may have various reasons for developing TP. Serologic testing for drug-dependent, platelet-reactive IgG and IgM abs may provide a means of identifying those in whom vancomycin should be discontinued.
Title: Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Description:
Abstract Numerous drugs are known to cause immune thrombocytopenia (TP) mediated by antibodies (abs) that bind to platelets only when the sensitizing drug is present in soluble form.
The widely used antibiotic, vancomycin, has been implicated as a cause of TP only in 8 case reports and little is known about antibodies possibly responsible for this complication.
We characterized clinical and serologic aspects of TP occurring in 39 patients during treatment with vancomycin.
In this group, TP developed after 1–27 days of treatment (median 6 days) and plt nadirs ranged from 1,000 to 60,000 plts/uL (median 14,000 plts/uL).
Bleeding occurred in 14 patients and contributed to a fatal outcome in 3.
TP persisted for 1–17 days after discontinuing vancomycin (median 7 days).
Platelets eventually returned to baseline in all surviving patients.
Serum obtained after the onset of TP was studied for vancomycin-dependent, platelet-reactive abs by flow cytometry and by solid phase ELISA using immobilized plt glycoproteins (GP) as targets.
Vancomycin-dependent antibodies detected in patients and normal subjects IgG only IgM only IgG + IgM No antibody Total Patients with TP 21 (54%) 5 (13%) 13 (33%) (0)%) 39 Normal individuals 58 (21%) 4 (1%) 1 (0%) 210 (77%) 273 Results of flow cytometric studies are summarized above.
All patients had IgG and/or IgM abs that reacted with normal plts in the presence, but not in the absence of vancomycin.
The IgG mean fluorescence intensity (MFI) signal in the presence of drug was 1.
6 to 32.
0 times stronger (mean ratio 5.
7) than that obtained in the absence of drug.
Vancomycin-dependent IgG abs were also identified in 59 of 273 normal individuals but were much weaker than abs detected in patients (p = 0.
004).
IgM abs (mean ratio 5.
7, range 1.
6 – 34) were found in 18 of 39 patients (46%).
Weaker IgM abs were found in only 5 of 273 normal subjects (1.
8%) (p = 0.
001).
Two patient abs studied in ELISA reacted preferentially with GPIIb/IIIa.
Studies to determine the frequency of abs in patients given vancomycin who do not develop TP are in progress.
These findings provide evidence that TP in patients given vancomycin can be caused by drug-dependent abs specific for GPIIb/IIIa that are stimulated by vancomycin exposure.
IgG and IgM abs in patients with TP are generally much stronger than drug-dependent, platelet-reactive immunoglobulins found in some normal subjects.
The significance of the latter abs is presently unknown.
Drug-dependent IgM abs are found almost exclusively in patients with vancomycin-associated TP and may be diagnostic.
Patients treated with vancomycin often have life-threatening bacterial sepsis and may have various reasons for developing TP.
Serologic testing for drug-dependent, platelet-reactive IgG and IgM abs may provide a means of identifying those in whom vancomycin should be discontinued.

Related Results

Probable Vancomycin-Induced Neutropenia
Probable Vancomycin-Induced Neutropenia
OBJECTIVE To report a case of vancomycin-induced neutropenia and provide a review of the literature. CASE SUMMARY A 64-year-old white man was treated with intravenous vancomycin 1....
Immature platelet fraction as a useful predictor of the aetiology of thrombocytopenia: experience from Oman
Immature platelet fraction as a useful predictor of the aetiology of thrombocytopenia: experience from Oman
Abstract Clinical evaluation of the possible aetiology of thrombocytopenia is important in the management of thrombocytopenia, which is concomitant with different disease...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Frequency of Thrombocytopenia in Malaria and its prognostic significance
Frequency of Thrombocytopenia in Malaria and its prognostic significance
BACKGROUND & OBJECTIVE: Thrombocytopenia is a common hematological manifestation of malaria, but locally there is limited data on the association of thrombocytopenia degree and...
Bleeding in neonates with severe thrombocytopenia: a retrospective cohort study
Bleeding in neonates with severe thrombocytopenia: a retrospective cohort study
Abstract Background Severe neonatal thrombocytopenia is a rare disease with multiple etiologies. Severe thrombocytopenia with bleeding is life-threa...

Back to Top